Anti-CD22 immunotoxin

Triphase Accelerator Announces Positive Updated Phase 1 Data with TRPH-222 in Non-Hodgkin’s Lymphoma

Retrieved on: 
Tuesday, February 22, 2022
Trillium, Neutropenia, Hematology, Cell, Cytopenia, DLBCL, Ontario Institute for Cancer Research, Therapy, Thrombocytopenia, Acute lymphoblastic leukemia, Oncology, Incidence, Division, Partnership, Growth, Pharmacokinetics, Pfizer, Drug development, Safety, FACIT, Roswell Park Comprehensive Cancer Center, SAN, Anti-CD22 immunotoxin, NR, CEO, B-cell lymphoma, Maitansine, MCL, ORR, Patient, CRS, CD22, AES, ADC, GLOBE, CRR, Mantle cell lymphoma, NHL, B-ALL, CD19, Toxicity, Follicular lymphoma, Control, Niclas, Lymphoma, TFL, Catalent, MD, Time, Pharmaceutical industry, MaRS Discovery District, Inotuzumab ozogamicin

The observed data support further clinical studies of TRPH-222, including combinations with other anti-tumor agents in B-cell lymphoma patients.

Key Points: 
  • The observed data support further clinical studies of TRPH-222, including combinations with other anti-tumor agents in B-cell lymphoma patients.
  • The drug, formerly called CAT-02-106, was developed by Catalent Biologics using its proprietary SMARTag technology and was licensed to Triphase Accelerator.
  • Triphase Accelerator is a private drug development company with a primary focus on oncology and operations in Toronto and San Diego.
  • Triphase Accelerator was founded by the Ontario Institute for Cancer Research (OICR) and FACIT, in partnership with Toronto Innovation Acceleration Partners (TIAP) and MaRS.

SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03

Retrieved on: 
Tuesday, November 30, 2021
Patient, SM03, CD22, Safety, B-cell lymphoma, Asthma, Company, Rheumatoid arthritis, Clinical trial, Mab, RA, Therapy, MTX, Research, Thirteenth, III, Twelfth, The Company, Methotrexate, Anti-CD22 immunotoxin, Lupus, Pharmaceutical industry

The patients currently in screening will be randomized by end of December 2021, given eligibility criteria are met.

Key Points: 
  • The patients currently in screening will be randomized by end of December 2021, given eligibility criteria are met.
  • SM03 (Suciraslimab), a potential global first-in-target anti-CD22 monoclonal antibody for the treatment of RA and potentially for the treatment of other immunological diseases, is currently in Phase III clinical trials in China.
  • The Phase III clinical trial is a multi-center, randomized, double-blind, placebo-controlled, parallel group study to confirm the clinical efficacy and long-term safety in active RA patients receiving methotrexate (MTX).
  • The efficacy and safety of Suciraslimab was previously evaluated in a phase II clinical study in moderate-to-severely active RA patients.